The past decade has witnessed ongoing progress in immune therapy to ameliorate human
health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the …

Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …

Background This study aimed to validate whether infusion of GD2-specific fourth-generation
safety-designed chimeric antigen receptor (4SCAR)-T cells is safe and whether CAR-T cells …

Dendritic cells (DCs) are antigen-presenting myeloid cells that regulate T cell activation,
trafficking and function. Monocyte-derived DCs pulsed with tumor antigens have been tested …

Background Aggressive primary brain tumors such as glioblastoma are uniquely
challenging to treat. The intracranial location poses barriers to therapy, and the potential for …

Adoptive cell therapy using chimeric antigen receptor (CAR) technology is one of the most
advanced engineering platforms for cancer immunotherapy. CAR-T cells have shown …

Glioma is the most common primary intracranial tumor and has the greatest prevalence of all
brain tumors. Treatment resistance and tumor recurrence in GBM are mostly explained by …

Simple Summary Glioblastoma is the most common brain cancer, and prognosis remains
dismal. Continued efforts to find better treatments have shown the promise of …

Cancer is characterized by uncontrolled cell growth, disrupted regulatory pathways, and the
accumulation of genetic mutations. These mutations across different types of cancer lead to …

Glioblastoma (GBM) is still an incurable tumor that is associated with high recurrence rate
and poor survival despite the current treatment regimes. With the urgent need for novel …